JCR Pharmaceuticals (JCRRF) News Today $4.25 0.00 (0.00%) As of 09/19/2025 Add Compare Share Share Headlines Stock AnalysisChartHeadlinesShort InterestBuy This Stock JCRRF Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period JCR Pharmaceuticals and Alexion Achieve Milestone in Collaborative Neurodegenerative Disease ProgramSeptember 19, 2025 | businesswire.comJCR Pharmaceuticals Celebrates its 50th Anniversary of Advancing Science and Changing LivesSeptember 12, 2025 | businesswire.comJCR Pharmaceuticals (OTCMKTS:JCRRF) Trading 12.4% Higher - What's Next?September 12, 2025 | americanbankingnews.comJCR Pharmaceuticals Presents Long-Term Clinical Data on Pabinafusp Alfa for the Treatment of Mucopolysaccharidosis Type II (MPS II) at ICIEM 2025September 8, 2025 | businesswire.comJCR Pharmaceuticals Selected for Japan's Regenerative Medicine CDMO Subsidy ProgramJuly 16, 2025 | businesswire.comJCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology PlatformJuly 15, 2025 | businesswire.comJCR Pharmaceuticals Enters License Agreement with Alexion for Proprietary JUST-AAV Capsids to be Used in the Development of Genomic MedicinesJuly 8, 2025 | businesswire.comJCR Pharmaceuticals Announces the Achievement of Enrollment in the JR-141 Global Phase III Clinical TrialJuly 2, 2025 | businesswire.comJCR Pharmaceuticals Announces Launch of Mucopolysaccharidosis (MPS) Type II Disease Awareness Film Featured in The Next Frontier SeriesJune 18, 2025 | businesswire.comJCR Pharmaceuticals Marks 50 Years of Innovation with Launch of One-of-a-Kind Global WebsiteJune 6, 2025 | businesswire.comJCRRF JCR Pharmaceuticals Co., Ltd.May 20, 2025 | seekingalpha.comJCR Pharmaceuticals Reports Significant Financial Losses for FY2024May 13, 2025 | tipranks.comJCR Pharmaceuticals to Present at the American Society of Gene and Cell Therapy 28th Annual MeetingMay 8, 2025 | businesswire.comNotice of Orphan Drug Designation for JR-446 for Mucopolysaccharidosis Type IIIB by the U.S. FDAMay 7, 2025 | uk.finance.yahoo.comJCR Pharmaceuticals Nominates New Audit & Supervisory Board MembersApril 25, 2025 | tipranks.comJCR Pharmaceuticals Begins Construction of New Drug Product PlantFebruary 25, 2025 | tipranks.comJCR Pharmaceuticals' Research Presentations at WORLDSymposiumâ„¢ 2025 Showcase Research from Its Investigational Treatments for Lysosomal Storage DisordersFebruary 5, 2025 | businesswire.comJCR Pharmaceuticals Showcases Promising Data at WORLDSymposium™ 2025February 5, 2025 | tipranks.comJCR Pharmaceuticals Co., Ltd. (4552) Gets a Hold from JefferiesJanuary 29, 2025 | markets.businessinsider.comJCR Pharmaceuticals to Present at the 21st Annual WORLDSymposium™ 2025January 28, 2025 | finance.yahoo.comJCR Pharmaceuticals to Showcase Innovative Therapies at WORLDSymposium 2025January 28, 2025 | tipranks.comJCR Pharmaceuticals and Modalis Therapeutics Advance Gene Therapy CollaborationJanuary 5, 2025 | tipranks.comJCR Pharmaceuticals and Modalis Advance Joint Gene Therapy ResearchJanuary 5, 2025 | tipranks.comJCR Pharmaceuticals and Modalis Therapeutics Announce Transition to the Next Phase of Joint Research Agreement for Development of Novel Gene TherapyJanuary 5, 2025 | businesswire.comJCR Pharmaceuticals doses first patient in paediatric growth hormone trialDecember 23, 2024 | msn.comJCR Pharmaceuticals Initiates Phase III Clinical Trial of JR-142 in Japan, a Long-Acting Growth Hormone TherapyDecember 20, 2024 | businesswire.comJCR Pharmaceuticals Launches Key JR-142 Clinical TrialDecember 19, 2024 | tipranks.comMEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Announce Initiation of First Dosing in Phase I/II Clinical Trial of JR-446 for Mucopolysaccharidosis Type IIIB in JapanDecember 5, 2024 | businesswire.comJCR Pharmaceuticals Initiates Clinical Trial for MPS IIIBDecember 3, 2024 | tipranks.comJCR Pharmaceuticals Faces Financial Decline Amid Strategic ChangesNovember 18, 2024 | tipranks.comJCR Pharmaceuticals Completes Share Buyback for Strategic GrowthOctober 31, 2024 | markets.businessinsider.comJCR Pharmaceuticals Initiates First Dosing in Phase I Clinical Trial of JR-441 for Mucopolysaccharidosis Type IIIAOctober 31, 2024 | businesswire.comJCR Pharmaceuticals Presents Preclinical Gene Therapy Research at the European Society of Gene and Cell Therapy 31st Annual CongressOctober 23, 2024 | businesswire.comJCR Pharmaceuticals Advances Gene Therapy ResearchOctober 23, 2024 | markets.businessinsider.comMesoblast: Undervalued Due To Remestemcel-L's Substantial Growth PotentialSeptember 30, 2024 | seekingalpha.comJCR Pharmaceuticals Highlights Innovative Gene Therapy Research at the 7th International Forum of Lysosomal DisordersJuly 19, 2024 | businesswire.comModalis Therapeutics Corporation (4883.T)May 25, 2024 | finance.yahoo.comJCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo® Technology for Neurodegenerative Disease in Research Collaboration with AlexionMarch 19, 2024 | finance.yahoo.comJCR Pharmaceuticals Co Ltd 4552March 2, 2024 | morningstar.comMJCR Pharmaceuticals Celebrates Rare Disease Day 2024 and Highlights Its Commitment to the Rare Disease CommunityFebruary 29, 2024 | finance.yahoo.comJCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2024 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage DisordersFebruary 14, 2024 | finance.yahoo.comJCR Pharmaceuticals earnings preview: what Wall Street is expectingJanuary 25, 2024 | markets.businessinsider.comJCR Pharmaceuticals to Present at the 20th Annual WORLDSymposium™ 2024January 25, 2024 | finance.yahoo.comJCR Announces Research Collaboration, Option and License Agreement with Alexion on Discovery of Oligonucleotide Therapeutics Using J-Brain Cargo® TechnologyDecember 21, 2023 | finance.yahoo.comJCR Pharmaceuticals and Takeda Pharmaceuticals Announce Discontinuation of Gene Therapy CollaborationDecember 21, 2023 | finance.yahoo.comU.S. FDA Grants Orphan Drug Designation to JR-441 for the Treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA)December 15, 2023 | finance.yahoo.comJCR Pharmaceuticals doses first patient in MPS IIIA trialNovember 13, 2023 | msn.comJCR Pharmaceuticals earnings preview: what to expectOctober 24, 2023 | markets.businessinsider.comJCR Pharmaceuticals Announces 52-Week Interim Data from its Global Phase I/II Study of JR-171 in Individuals with Mucopolysaccharidosis Type I (MPS I)September 29, 2023 | finance.yahoo.comJCR Pharmaceuticals Shares Jump After It Raises Earnings GuidanceSeptember 28, 2023 | marketwatch.com Get JCR Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for JCRRF and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JCRRF Media Mentions By Week JCRRF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. JCRRF News Sentiment▼0.000.73▲Average Medical News Sentiment JCRRF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. JCRRF Articles This Week▼10▲JCRRF Articles Average Week Get the Latest News and Ratings for JCRRF and Related Stocks Enter your email address to receive the latest news and analysts' ratings for JCR Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies AZNCF News CMOPF News CSPCY News KYKOF News MAYNF News OTSKF News RHHVF News SNYNF News SCLXW News VRBCF News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:JCRRF) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding JCR Pharmaceuticals Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share JCR Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free JCRRF Stock Alerts